Doxorubicin-related cardiotoxicity: review of fundamental pathways of cardiovascular system injury

Cardiovasc Pathol. 2024 Nov-Dec:73:107683. doi: 10.1016/j.carpath.2024.107683. Epub 2024 Aug 5.

Abstract

Over the years, advancements in the field of oncology have made remarkable strides in enhancing the efficacy of medical care for patients with cancer. These modernizations have resulted in prolonged survival and improved the quality of life for these patients. However, this progress has also been accompanied by escalation in mortality rates associated with anthracycline chemotherapy. Anthracyclines, which are known for their potent antitumor properties, are notorious for their substantial cardiotoxic potential. Remarkably, even after 6 decades of research, a conclusive solution to protect the cardiovascular system against doxorubicin-induced damage has not yet been established. A comprehensive understanding of the pathophysiological processes driving cardiotoxicity combined with targeted research is crucial for developing innovative cardioprotective strategies. This review seeks to explain the mechanisms responsible for structural and functional alterations in doxorubicin-induced cardiomyopathy.

Keywords: Cardio-oncology; Cardiotoxicity; Chemotherapy; Doxorubicin.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibiotics, Antineoplastic* / adverse effects
  • Cardiomyopathies / chemically induced
  • Cardiomyopathies / pathology
  • Cardiomyopathies / physiopathology
  • Cardiotoxicity*
  • Doxorubicin* / adverse effects
  • Humans
  • Signal Transduction / drug effects

Substances

  • Doxorubicin
  • Antibiotics, Antineoplastic